This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

This study has been completed.
Information provided by:
Telik Identifier:
First received: April 7, 2003
Last updated: July 21, 2011
Last verified: May 2006
The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations.

Condition Intervention Phase
Ovarian Neoplasms Drug: TLK286 HCl for injection Drug: topotecan hydrochloride for injection Drug: doxorubicin HCl liposome injection Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 3 Randomized Study of TLK286 (Telcyta) Versus Doxil/Caelyx or Hycamtin as Third-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-1 (Assessment of Survival In Solid Tumors-1)]

Resource links provided by NLM:

Further study details as provided by Telik:

Estimated Enrollment: 440
Study Start Date: June 2003
Study Completion Date: December 2006
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion criteria include:

  • Considered platinum refractory or resistant according to standard criteria
  • Progressed during or following completion of one second-line treatment with Doxil/Caelyx or Hycamtin
  • Histologically or cytologically confirmed diagnosis of epithelial cancer of the ovary, fallopian tube, or primary peritoneal cancer
  • Measurable disease according to RECIST criteria with documented tumor progression

Exclusion criteria include:

  • Treatment with second-line chemotherapy other than Doxil/Caelyx or Hycamtin
  • History of whole pelvis radiation therapy within 12 months of enrollment
  • Clinically significant cardiac disease
  • Evidence of gross hematuria at the time of study entry
  • Any signs of intestinal obstruction interfering with nutrition at the time of study entry
  • Pregnant or lactating women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00057720

  Show 320 Study Locations
Sponsors and Collaborators
  More Information

Responsible Party: Gail Brown, MD Chief Medical Officer, Telik, Inc Identifier: NCT00057720     History of Changes
Obsolete Identifiers: NCT00078884
Other Study ID Numbers: TLK286.3017
Study First Received: April 7, 2003
Last Updated: July 21, 2011

Keywords provided by Telik:

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Topoisomerase I Inhibitors processed this record on September 25, 2017